Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review
Mycobacterial infections are considered to a serious challenge of medicine, and the
emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis …
emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis …
Buruli ulcer (Mycobacterium ulcerans infection)
DS Walsh, F Portaels, WM Meyers - Transactions of the Royal …, 2008 - academic.oup.com
Mycobacterium ulcerans is an emerging infection that causes indolent, necrotizing skin
lesions known as Buruli ulcer (BU). Bone lesions may include reactive osteitis or …
lesions known as Buruli ulcer (BU). Bone lesions may include reactive osteitis or …
Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer
JR Wallace, KM Mangas, JL Porter… - PLoS neglected …, 2017 - journals.plos.org
Addressing the transmission enigma of the neglected disease Buruli ulcer (BU) is a World
Health Organization priority. In Australia, we have observed an association between …
Health Organization priority. In Australia, we have observed an association between …
Phage Therapy Is Effective against Infection by Mycobacterium ulcerans in a Murine Footpad Model
G Trigo, TG Martins, AG Fraga… - PLoS neglected …, 2013 - journals.plos.org
Background Buruli Ulcer (BU) is a neglected, necrotizing skin disease caused by
Mycobacterium ulcerans. Currently, there is no vaccine against M. ulcerans infection …
Mycobacterium ulcerans. Currently, there is no vaccine against M. ulcerans infection …
[PDF][PDF] Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update
DP O'Brien, G Jenkin, J Buntine, CM Steffen… - 2014 - mja.com.au
The Medical Journal of Australia Page 1 Clinical focus 267 MJA 200 (5) · 17 March 2014 The
Medical Journal of Australia ISSN: 0025729X 17 March 2014 200 5 267-270 ©The Medical …
Medical Journal of Australia ISSN: 0025729X 17 March 2014 200 5 267-270 ©The Medical …
[PDF][PDF] Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers
World Health Organization - 2012 - apps.who.int
This document is intended to guide health workers in areas where Mycobacterium ulcerans
disease (Buruli ulcer) occurs, and also those in nonendemic areas, in providing optimal …
disease (Buruli ulcer) occurs, and also those in nonendemic areas, in providing optimal …
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of …
RO Phillips, FS Sarfo, MK Abass, J Abotsi… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Buruli ulcer, an ulcerating skin disease caused by Mycobacterium ulcerans infection, is
common in tropical areas of western Africa. We determined the clinical and microbiological …
common in tropical areas of western Africa. We determined the clinical and microbiological …
Mycolactone diffuses into the peripheral blood of buruli ulcer patients-implications for diagnosis and disease monitoring
FS Sarfo, F Le Chevalier, NG Aka… - PLoS neglected …, 2011 - journals.plos.org
Background Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU), is unique
among human pathogens in its capacity to produce a polyketide-derived macrolide called …
among human pathogens in its capacity to produce a polyketide-derived macrolide called …
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)
RR Yotsu, M Richardson, N Ishii - Cochrane Database of …, 2018 - cochranelibrary.com
Background Buruli ulcer is a necrotizing cutaneous infection caused by infection with
Mycobacterium ulcerans bacteria that occurs mainly in tropical and subtropical regions. The …
Mycobacterium ulcerans bacteria that occurs mainly in tropical and subtropical regions. The …
Successful Outcomes with Oral Fluoroquinolones Combined with Rifampicin in the Treatment of Mycobacterium ulcerans: An Observational Cohort Study
DP O'Brien, A McDonald, P Callan… - PLoS neglected …, 2012 - journals.plos.org
Background The World Health Organization currently recommends combined streptomycin
and rifampicin antibiotic treatment as first-line therapy for Mycobacterium ulcerans infections …
and rifampicin antibiotic treatment as first-line therapy for Mycobacterium ulcerans infections …